HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.1%

Neg 0% Neu 89.1% Pos 0%

HC Wainwright & Co. analyst Matthew Keller reiterates Kyntra Bio (NASDAQ:KYNB) with a Buy and maintains $43 price target.